It has been developed light-activated derivatives of the anti-epileptic drug carbamazepine to treat neuropathic pain. These compounds, which show analgesic effects when activated by light, can inhibit...
Read moreCon este acuerdo, la biofarmacéutica española AbilityPharma inicia la fabricación de su fármaco principal ABTL0812 para administrar a pacientes con cáncer de páncreas en el marco del ensayo clí...
Read moreThe core idea of Open innovation is that companies leverage the ideas and resources of external actors such as customers, suppliers, universities, start-ups, etc.
Read moreEl Comité de Evaluación de Medicamentos de uso humano de la Agencia Española del Medicamento y Productos Sanitarios (AEMPS) ha dado el visto bueno al ARI0002h para su aprobación como medicamento d...
Read moreStrategic alliances are crucial for success in the global pharma market. By forming partnerships, companies can access complementary capabilities, share risks, enhance market access, and leverage shar...
Read moreProducts & Technology, a Rubió Group company, has undertaken research and development (R&D) to create a medication aimed at treating insomnia in children with Attention Deficit Hyperactivity Disorder...
Read moreOXO-001 es un fármaco no hormonal, el primero en su clase, que actúa directamente sobre el endometrio (el revestimiento interno del útero) para hacerlo más propicio para la implantación del embri...
Read moreCK-0045 induced exposure-dependent reductions in body weight and improvement of key metabolic parameters in participants with obesity
Read moreThe European Medicines Agency (EMA) recently approved the combination of novel AKT inhibitor capivasertib with fulvestrant for patients with hormone receptor (HR)-positive, HER2-negative advanced or m...
Read moreAbilityPharma (Ability Pharmaceuticals, S.L.), una compañía biofarmacéutica catalana especializada en el desarrollo de fármacos oncológicos, ha anunciado hoy que su socio en China, SciClone (SciC...
Read moreAbilityPharma announces that the World Health Organization (WHO) has recommended ABTL0812, a first-in-class oral drug for cancer treatment that causes selective death of cancer cells through autophagy...
Read moreOryzon Genomics announced today that its management will give an update on corporate progress at several international events in September.
Read more